Whole slide imaging (WSI) or virtual microscopy enables slide digitization and is defined as the process by which a digital image of an entire glass slide is acquired, producing a digital slide. The number of studies evaluating WSI in consultation models is small; however, available data is encouraging. The US Food and Drug Administration (FDA) has not yet approved the use of WSI systems for H&E diagnosis, although some of WSI companies have already initiated the approval process. The Digital Pathology Association suggested that the manufacturers interested in marketing whole slide imaging devices should submit de-novo applications to the Food and Drug Administration. Many manufacturing companies are also looking for opportunities in different market economies, like Europe and Canada, where the policies are not stringent and are better integrated. In Southern Sweden, the whole slide system is widely used for primary diagnosis. The WSI telepathology program at University Health Network (UHN) in Canada has recently been expanded to provide primary frozen-section support, without incident, to a hospital 400 miles north of Toronto, where there is no on-site pathologist.
In recent years, improvements in computing power have reduced scanning times to 2-6 minutes depending on the size of the section. The Hamamatsu NanoZoomer 2.0-HT has reduced the time for scanning slides to approximately 1 minute, while the Aperio ScanScope AT pathology slide scanner can process about 31 slides per hour in its single-button automated mode. The Olympus VS120 x40 objective lens system recently won the best image award (0.16 µm/pixel) in the resolution category. Several commercial virtual microscopy companies have developed software for virtual microscopy of tissue microarrays, which have become increasingly popular in diagnostic studies in the recent years.
Drivers and Restraints:
Factors like growing popularity of virtual slides, as compared to physical slides, technological advances in whole slide imaging and growing research in drug discovery are driving the whole slide imaging market. Market restraints include reimbursement issues, pending regulatory approvals, and the high cost of whole slide imaging systems.
The whole slide imaging market can be segmented by -
Pharmaceutical and Biotechnology companies
Academic and government research institutes
Hospitals and pathology labs
Hospitals and pathology labs account for the highest share in the whole slide imaging market. This is attributed to the increasing demand for accurate and faster diagnosis.
The whole slide imaging market can also be segmented by geography into North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. North America accounts for the highest market share due to the presence of a large number of hospitals and labs adopting whole slide imaging.
- 3DHISTECH Ltd.
Market analysis for the global whole slide imaging screening market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints opportunities and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global whole slide imaging market.
Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
3. Executive Summary
4. Key Inferences
5. Market Characterization
5.1 Current Market Scenario
5.2 Market Overview
5.3 Market Dynamics
5.4 Market Drivers
5.4.1 Growing Popularity of Virtual Slides as Compared To Physical Slides.
5.4.2 Technological Advancements in Whole Slide Imaging
5.4.3 Growing Research in Drug Discovery
5.5 Market Restraints
5.5.1 Reimbursement Issues
5.5.2 Pending Regulatory Approvals
5.5.3 High Cost of Whole Slide Imaging Systems
5.6 Porters Five Force Analysis
5.6.1 Bargaining Power of Suppliers
5.6.2 Bargaining Power of Buyers
5.6.3 Degree of Competition
5.6.4 Threat of Substitution
5.6.5 Threat of New Entrants
5.6.6 Global Market Segmentation
126.96.36.199 By Application
188.8.131.52 By End-User
184.108.40.206 Pharmaceutical and Biotechnology Companies
220.127.116.11 Academic and Government Research Institutes
5.6.8 Hospitals and Pathology labs
18.104.22.168 Global Whole Slide Imaging Systems Market - Segmentation by Geography
22.214.171.124 North America
5.6.11 South Korea
126.96.36.199 The Middle East and Africa
5.6.12 South Africa
188.8.131.52 Latin America
8. Company Profiles
8.1 Olympus Corporation
8.2 Philips Healthcare
8.3 Definiens AG
8.4 Digipath Inc
8.5 Leica Microsystems
8.6 Ventana Medical Systems, Inc
8.7 Hamamatsu Photonics K.K.
8.8 Mikroscan Technologies
8.9 Visiopharm A/S
8.10 3DHISTECH Ltd.
8.11 Omnyx LLC
9. Future Outlook